Navigation Links
Transdel Pharmaceuticals Appoints Mr. Lynn Swann, Pro-Football Hall of Famer, ABC Sports Broadcaster, and Former Chairman of the President's Council on Physical Fitness and Sports, to Board of Directors
Date:11/24/2008

LA JOLLA, Calif., Nov. 24 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP), a specialty pharmaceutical company focused on the development and commercialization of non-invasive topically targeted medications, today announced that Mr. Lynn Swann has been appointed to the Company's Board of Directors.

Mr. Swann is president of Swann, Inc., a consulting firm specializing in marketing and communications and managing director of Diamond Edge Capital Partners, LLC, a New York-based finance company.

Mr. Swann currently serves on the Board of Directors of H.J. Heinz Company, Hershey Entertainment and Resorts Company and Harrah's Entertainment, Inc. He was also chairman of the President's Council on Physical Fitness and Sports from 2002-2005. A former all-pro wide receiver for the Pittsburgh Steelers and 2001 Hall of Famer, he spent twenty-nine years with ABC Sports as a sports analyst and broadcaster before retiring in 2006.

Active in community affairs, Mr. Swann is national spokesman and former board president of Big Brothers and Sisters of America and former director of the Pittsburgh Ballet Theatre. Mr. Swann holds a B.A. degree in public relations from the University of Southern California.

Dr. Juliet Singh, President and CEO of Transdel Pharmaceuticals, Inc., commented, "Over the course of his life in the public eye, Mr. Swann has proven himself to be a great leader both on and off the field. Transdel is extremely fortunate to strengthen its Board of Directors by adding an individual as experienced and accomplished as Mr. Swann. He is a tremendous addition to the Company's Board especially given his extensive and diverse business background and business affiliations. We are delighted to welcome him to the team and look forward to his contributions in growing Transdel and expanding the Company's business opportunities."

Mr. Swann added: "I am pleased and honored to be joining the Board of Directors of Transdel Pharmaceuticals and look forward to contributing to the company's future success. Transdel's transdermal delivery platform technology is truly impressive. Given the growth of sports medicine, I am particularly excited about the company's lead drug, Ketotransdel(TM), its topical NSAID cream formulation for pain management and the unmet medical need that it will potentially fulfill."

About Transdel Pharmaceuticals, Inc.

Transdel Pharmaceuticals, Inc. (OTCBB: TDLP - News) is a specialty pharmaceutical company developing non-invasive, topically delivered medications. The Company's innovative patented proprietary Transdel(TM) cream formulation technology is designed to facilitate the effective penetration of drugs through the tough skin barrier to reach the target underlying tissues. In the case of Ketotransdel(TM), the Transdel(TM) cream allows the active ingredient ketoprofen to reach the target soft tissue and exert its well-known anti-inflammatory and analgesic effects. The Company is also investigating other drug candidates and treatments for transdermal delivery using the patented Transdel(TM) platform technology for products in pain management and other therapeutic areas. For more information, please visit http://www.transdelpharma.com.

Safe Harbor Statement

The statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

     Contact:
     John Lomoro, CFO
     Transdel Pharmaceuticals, Inc.
     858-457-5300
     E-mail: johnl@transdelpharma.com

     Or

     The Investor Relations Group
     Investor Relations:
     Rachel Colgate / Michael Crawford
     212-825-3210
     or
     Media Relations
     Laura Colontrelle / Janet Vasquez
     212-825-3210

'/>"/>
SOURCE Transdel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Transdel Pharmaceuticals to Present at Cowen and Companys 28th Annual Health Care Conference
2. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
3. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
4. Keryx Biopharmaceuticals Receives Nasdaq Notification
5. Purdue Pharma L.P. Announces a Global Strategic Alliance With Infinity Pharmaceuticals to Advance Discovery and Development Programs in Oncology and Neuropathic Pain
6. FDA Accepts Vanda Pharmaceuticals Iloperidone Resubmission and Sets New Action Date
7. Amylin Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
8. MiddleBrook Pharmaceuticals Reports Third Quarter 2008 Financial Results
9. MAP Pharmaceuticals Reports Third Quarter of 2008 Financial Results
10. Ferring Pharmaceuticals Promotes William Garbarini to Vice President of New Orthopaedics and Urology Business Unit
11. Alexza Pharmaceuticals Announces Upcoming Conference Participation and Webcasts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... 2017 , ... In the United States alone, up to 36% of primary ... of metastatic brain tumors(3). Though most meningiomas are benign, metastatic brain tumors are known ... effective treatment options, the San Diego Gamma Knife Center offers a precision-medicine ...
(Date:3/29/2017)... ... ... is the main cause of hay fever in the United States, with an estimated 95 ... May to July each year; with the worst time for sufferers being June and July. ... http://www.haymax.us ) provide an effective defense against grass pollen; they are proven in independent studies ...
(Date:3/29/2017)... (PRWEB) , ... March 30, 2017 , ... Sublime Naturals ... "Spice of Life" or "Wonder Spice", it has been used for thousands of years. ... the East," says Heshelow, author of " Turmeric: How to Use it For Your ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... a Walgreens store in Mississippi. AngioGenesis Labs, makers of HeartBoost, BrainBest and BeautyBest, ... southeastern states. Ingredients in HeartBoost, an over the counter heart healthy drink, can ...
(Date:3/29/2017)... ... March 29, 2017 , ... Patients ... in Carnegie, OK, from Dr. Jamie Cameron, with or without a referral. The ... traditional orthodontic treatment. Depending on each patient’s case, treatment with the FASTBRACES system ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... ALBANY, New York , March 29, 2017 ... has recently published a report, which provides an ... According to the study, nearly 242 companies are ... highly fragmented and competitive. With the leading companies, ... and Purdue Pharma LP, focusing aggressively on various ...
(Date:3/29/2017)... Research and Markets has announced the addition ... their offering. ... The global lifestyle drugs market to grow at a CAGR of ... Lifestyle Drugs Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
(Date:3/29/2017)... 29, 2017 Varian Medical Systems (NYSE: ... the second quarter of fiscal year 2017 following the close ... release will be followed by a teleconference available to all ... a link to the conference call webcast will be available ... the teleconference call and replay: ...
Breaking Medicine Technology: